William Blair Analysts Cut Earnings Estimates for Jasper Therapeutics, Inc. (NASDAQ:JSPR)

Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) - Stock analysts at William Blair dropped their FY2024 earnings estimates for shares of Jasper Therapeutics in a research note issued on Tuesday, August 13th. William Blair analyst M. Phipps now expects that the company will post earnings of ($3.88) per share for the year, down from their prior forecast of ($3.86). The consensus estimate for Jasper Therapeutics' current full-year earnings is ($4.41) per share. William Blair also issued estimates for Jasper Therapeutics' Q4 2024 earnings at ($0.92) EPS, FY2025 earnings at ($4.05) EPS, FY2026 earnings at ($3.75) EPS and FY2027 earnings at ($3.13) EPS.

A number of other research analysts have also commented on JSPR. BTIG Research started coverage on shares of Jasper Therapeutics in a research report on Monday, July 8th. They set a "buy" rating and a $90.00 price target for the company. Stifel Nicolaus started coverage on shares of Jasper Therapeutics in a research report on Thursday, June 27th. They issued a "buy" rating and a $86.00 target price for the company. Royal Bank of Canada cut their target price on shares of Jasper Therapeutics from $70.00 to $68.00 and set an "outperform" rating for the company in a research report on Wednesday. HC Wainwright restated a "buy" rating and set a $65.00 price target on shares of Jasper Therapeutics in a research report on Tuesday. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Jasper Therapeutics in a research report on Tuesday, June 18th. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $73.43.

Jasper Therapeutics Trading Up 0.7 %

Shares of JSPR traded up $0.12 during mid-day trading on Thursday, reaching $18.10. 210,901 shares of the stock traded hands, compared to its average volume of 135,166. The firm has a fifty day moving average price of $20.89 and a 200 day moving average price of $22.21. The company has a market cap of $272.66 million, a price-to-earnings ratio of -3.21 and a beta of 2.21. Jasper Therapeutics has a 1 year low of $4.00 and a 1 year high of $31.01.

Jasper Therapeutics (NASDAQ:JSPR - Get Free Report) last issued its earnings results on Tuesday, May 14th. The company reported ($1.03) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.26) by $0.23.

Hedge Funds Weigh In On Jasper Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Fernwood Investment Management LLC raised its stake in Jasper Therapeutics by 8.8% in the fourth quarter. Fernwood Investment Management LLC now owns 494,706 shares of the company's stock worth $390,000 after buying an additional 40,000 shares in the last quarter. Monaco Asset Management SAM bought a new position in Jasper Therapeutics in the fourth quarter worth about $197,000. Ieq Capital LLC bought a new position in Jasper Therapeutics in the fourth quarter worth about $43,000. Opaleye Management Inc. bought a new position in Jasper Therapeutics in the fourth quarter worth about $3,144,000. Finally, Kingdon Capital Management L.L.C. raised its stake in Jasper Therapeutics by 16.4% in the fourth quarter. Kingdon Capital Management L.L.C. now owns 3,540,000 shares of the company's stock worth $2,793,000 after buying an additional 500,000 shares in the last quarter. 79.85% of the stock is owned by institutional investors.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.